What are the specific usage and dosage of Lapatinib/Talisat?

Lapatinib (Lapatinib) is an oral small molecule tyrosine kinase inhibitor that can simultaneously inhibit the signaling of the HER2 and EGFR pathways. It is an important targeted drug for HER2-positive breast cancer . The drug was developed by GlaxoSmithKline (GSK) under the trade name Tykerb and has been approved in many countries around the world for the treatment of recurrent or metastatic breast cancer. Its administration method is flexible, but the dosage and combination regimen must strictly follow medical guidance to ensure efficacy and reduce the risk of toxicity.

In clinical use, the most common combination regimen of lapatinib is with capecitabine. The recommended dose is lapatinib 1250 mg once daily, taken orally on an empty stomach, that is, at least one hour before or after meals. The recommended dose of capecitabine used in combination with it is 2000 mg/m²/day, taken orally in two doses, about 12 hours apart, with 14 days of continuous medication followed by 7 days of rest, forming a complete cycle of 21 days. Capecitabine should be taken with or within 30 minutes of food to reduce gastrointestinal irritation.

Another common regimen is the combination of lapatinib and letrozole, which is suitable for postmenopausal patients with hormone receptor-positive and HER2-positive metastatic breast cancer. At this time, the dose of lapatinib is 1500 mg once a day, and it is still recommended to take it on an empty stomach; the dose of letrozole is 2.5 mg once a day. The two drugs work synergistically through different targets - letrozole inhibits estrogen synthesis, while lapatinib blocks HER2 signaling, thereby dually inhibiting tumor cell growth.

It should be noted that the daily dose of lapatinib should be taken in one go. It is not recommended to take it in divided doses to ensure the stability of blood concentration and the persistence of drug effect. If adverse reactions such as decreased heart function, severe diarrhea, abnormal liver function, etc. occur, the doctor will adjust the dose or temporarily discontinue the drug based on the actual situation. Since lapatinib is mainly metabolized by CYP3A4, concomitant use with strong CYP3A4 inhibitors or inducers should be avoided to prevent abnormal drug concentrations.

Reference materials:https://medlineplus.gov/druginfo/meds/a607055.html